TAVI in low-risk patients

Evidence supports a role for TAVI in low-risk patients

Edwards-TAVI-patient-active-low-risk

TAVI can provide optimal outcomes to your low-risk patients1

In the PARTNER 3 Trial, TAVI, compared with surgery, resulted in superior clinical outcomes, improved quality of life and faster discharge for sAS patients.1*

Results

46%

reduced risk at 1 year in all-cause death, stroke or rehospitalisation (8.5% vs 15.1% for surgery), p=0.0011

1%

death or disabling stroke at 1 year (vs 2.9% for surgery), p=0.031

4-day

shorter length of hospital stay (3 vs 7 days for surgery), p<0.001 1

1-, 6- and 12- month

improvement in health status (compared to surgery)2

* The PARTNER 3 Trial proved SAPIEN 3 TAVI is superior to surgery on the primary endpoint (all-cause death, all stroke or rehospitalisation) and multiple prespecified secondary endpoints in low-risk patients.

Growing evidence in TAVI is leading to new recommendations

ESC/EACTS guidelines advise that surgical risk stratification is only one consideration when selecting the optimal treatment strategy, other factors include local resources, the patient’s life expectancy, expected quality of life and personal preference as well as using the latest outcome data.3, 4

Bridging the gap between guidelines update

The 2020 consensus paper of the German Society for Cardiology (DGK) and the German Society for Thoracic, Cardiac and Vascular Surgery (DGTHG) on TAVI 2020 recommends:4
≤ 70
years old
sAVR
70 - 75
years old
TAVI
evaluation
> 75
years old
TAVI

Refer your severe aortic stenosis patients for a Heart Team evaluation, irrespective of surgical risk.

See how the PARTNER 3 Trial and the consensus paper may change the AS treatment landscape.

Stay informed with our newsletter

Our monthly updates provide you the latest developments in TAVI and aortic stenosis.     Read more

References

  • 1Mack MJ, Leon MB, Thourani VH, et al. N Engl J Med. 2019;380(18):1695-1705.
  • 2Baron SJ, Magnuson EA, Lu M, et al. J Am Coll Cardiol 2019; 74(23):2833-2842.
  • 3Baumgartner H, Falk V, Bax JJ et al. Eur Heart J 2017;38(36):2739–2791.
  • 4Kuck K et al. Cardiologist 2020;14:182-204.

Content relating to Tavi.today is intended for healthcare professionals. Click OK to confirm you are a healthcare professional and proceed.

Skip to content